Expressions of ERβ and its variants ERβ1 and ERβcx in breast cancer and their clinical significance

doi:10.3877/cma.j.issn.1674-0807.2009.04.004

Abstract

Abstract:

Objective

To investigate the difference in the expressions of estrogen receptorβ(ERβ),and its variants ERβ1 and ERβcx in human epithelial growth factor receptor 2(HER-2)positive and negative breast cancer,and analyze the expressions of estrogen receptorα(ERα)and progesterone receptor(PR),and their association with clinical stage and axillary lymph node status.

Methods

Group sequential design and simple random sampling were used for the study.From Dec 2004 to Dec 2007,51 cases of HER-2()and 53 cases of HER-2(-)breast invasive ductal carcinoma were randomly selected from the First Affiliated Hospital of Sun Yat-sen University to separately detect the expressions of ERα,ERβ,ERβ1 and ERβcx and PR in breast cancer,and analyze their relationships with TNM stage and axillary lymph node metastases,and then analyze the lymph node status of the HER-2()group and the HER-2(-)group using Chi-square test,analyze the TNM stage and the expressions of ERα,PR,ERβ,ERβ1 and ERβcx of HER-2()and HER-2(-)groups using Wilcoxon rank sum test.The relationship of these index in the two groups were analyzed by Spearman rank correlation respectively.

Results

The positive rate of lymph node metastases in both the HER-2()and HER-2(-)patients had no significant difference.In both the HER-2()and HER-2(-)groups there were no statistical differences in clinical stage and axillary lymph node metastasis(P＞0.050).In the HER-2()group the positive expression rates of ERα,ERβ,ERβ1,ERβcx and PR were lower than in the HER-2 (-)group,with statistically significant differences between the two groups(P ＜0.050).In the HER-2 ()group,the expression of ERβ1 was positively correlated with ERα,and ERβcx expression was positively correlated with PR(P＜0.050),but ERβ,ERβ1 and ERβcx were found irrelevant with TNM stages and axillary lymph node metastasis(P＞0.050).In the HER-2 (-)group,the expressions of ERβ1 and ERβcx were both positively correlated with ERβ,ERαand PR(P＜0.050).ERα,PR,ERβ,ERβ1 and ERβcx were all irrelevant with TNM stages and axillary lymph node metastasis(P＞0.050).

Conclusion

ERβ1 and ERβcx could be considered as favorable prognostic markers of breast cancer.Further study is needed to explore their correlation with survival of breast cancer patients after treatment.

Key words: Breast neoplasms, Estrogen Receptorα, Estrogen Receptorβ, Estrogen Receptorβ1, Estrogen Receptorβcx

Jia-ni WANG, Ren-bin LIU, Abdalwali·Thabit Mohamed, Hui-zhen LIANG, Zhuang-hong WU, Wen-hui ZHang. Expressions of ERβ and its variants ERβ1 and ERβcx in breast cancer and their clinical significance[J]. Chinese Journal of Breast Disease(Electronic Edition), 2009, 03(04): 387-397.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2009.04.004

https://zhrxbzz.cma-cmc.com.cn/EN/Y2009/V03/I04/387

Figures/Tables 16

References 23

[1]	Kuiper G G,Enmark E,Peltohuikko M,et al.Cloning of a novel receptor expressed in rat prostate and ovary.Proc Natl Acad Sci USA,1996,93: 5925-5930.
[2]	梁燕.淋巴结阳性乳腺癌的亚型及其对多西紫杉醇的反应: BCIRG001 试验中免疫组化分类法的应用.中华乳腺病杂志: 电子版,2009,3: 239-241.
[3]	Shaaban A M ,O'Neill P A,Davies M P,et al.Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia.Am J Surg Pathol ,2003,27: 1502-1512.
[4]	Ellis I O,Dowsett M,Bartlett J,et al.Recommendations for HER-2 testing in the UK.Clin Pathol,2000,53: 890-892.
[5]	纪小龙,施作霖.诊断免疫组织化学.北京: 军事医学科学出版社,1997: 62.
[6]	Mosselman S,Ploman J,Djkema R.ERβ: identification and characterization of a novel human estrogen receptor.FEBS Lett,1996,392: 49-53.
[7]	Park B W,Kim K S,Heo M K,et al.Expression of estrogen receptor-beta in normal mammary and tumor tissues: is it protective in breast carcinogenesis?Breast Cancer Res Treat,2003,80: 79-85.
[8]	Omoto Y,Inoue S,Ogawa S,et al.Clinical value of the wild-type estrogen receptor beta expression in breast cancer.Cancer Letters,2001,163: 207-212.
[9]	Poola I,Clarke R,Witty R,et al.Functionally active estrogen receptor isoform profiles in the breast tumors of African American women are different from the profiles in breast tumors of Caucasian women.Cancer,2002,94: 615-623.
[10]	La Zennec G,Bresson D,Lucas A,et al.ER beta inhibits proliferation and invasion of breast cancer cells.Endocrinology,2001,142: 4120-4130.
[11]	Moore J T,Mc Kee D D,SlentzKesler K,et al.Cloning and characterization of human estrogen receptor βisoforms.Biochem Biophys Res Commun,1998,247: 75-78.
[12]	Poola I,Abraham J,Baldwin K,et al.Estrogen receptorsβ4 andβ5 are full-length functionally distinct ERβisoforms: cloning from human ovary and functional characterization.Endocrine,2005,27: 227-238.
[13]	Leung Y K,Mak P,Hassan S,et al.Estrogen receptor(ER)-βisoforms: a key to understanding ERβsignaling.Proc Natl Acad Sci USA,2006,103: 13 162-13 167.
[14]	Paruthiyil S,Parmar H,Kerekatte V,et al.Estrogen receptorβinhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest.Cancer Res,2004,64: 423-428.
[15]	Lazennec G,Bresson D,Lucas A,et al.ERβinhibits proliferation and invasion of breast cancer cells.Endocrinology,2001,142: 4120-4130.
[16]	Pettersson K,Delaunay F,Gustafsson J A.Estrogen receptorβacts as a dominant regulator of estrogen signaling.Oncogene,2000,19: 4970-4978.
[17]	Vesna M,Dragica N V,Nikola T,et al.Expression of estrogen receptorβisoform(ERβ1)and ERβ5 splice variant mRNAs in sporadic breast cancer.Cancer Res Clin Oncol,2007,133: 571-579.
[18]	Ahr A,Karn T,Solbach C,et al.Identification of high risk breast cancer patients by gene expression profiling.Lancet,2002,359: 131-132.
[19]	Ahr A,Holtrich U,Solbach C,et al.Molecular classification of breast cancer patients by gene expression profiling.J Pathol,2001,195: 312-320.
[20]	Saji S,Omoto Y,Shimizu C,et al.Expression of estrogen receptor(ER)(β)cx protein in ER(α)-positive breast cancer: specific correlation with progesterone receptor.Cancer Res,2002,62: 4849-4853.
[21]	Shaaban A M,Green A R,Suchita K,et al.Nuclear and cytoplasmic expression of ERβ1,ERβ2,and ERβ5 identifies distinct prognostic outcome for breast cancer patients.Clin Cancer Res,2008,14: 5228-5235.
[22]	Shaaban A M,Jarvis C,Moore F,et al.Prognostic significance of estrogen receptorβin epithelial hyperplasia of usual type with known outcome.AmJ Surg Pathol,2005,29: 1593-1599.
[23]	Bates G J,Fox S B,Han C,et al.Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptorβin primary invasive breast carcinomas.Breast Cancer Res Treat,2008,111: 453-459.

HER-2	例数	临床分期(例)				淋巴结转移			ERα(%)	PR(%)	ERβ(%)	ERβ1(%)	ERβ_CX(%)
HER-2	例数	Ⅰ期	Ⅱ期	Ⅲ期	Ⅳ期	阳性数	阴性数	阳性率	ERα(%)	PR(%)	ERβ(%)	ERβ1(%)	ERβ_CX(%)
()	51	6	32	11	2	21	30	41.18%	0.00(40.00)	50.00(80.00)	15.00(70.00)	0.00(50.00)	35.00(35.00)
(-)	53	9	33	9	2	28	25	52.83%	80.00(84.98)	60.00(70.00)	50.00(67.50)	75.00(32.50)	75.00(47.50)
统计量		-0.806^a				1.417^b			-4.825^a	-2.171^a	-2.137^a	-5.509^a	-3.663^a
P值		0.420				0.234			0.000	0.030	0.033	0.000	0.000

HER-2	例数	临床分期(例)				淋巴结转移			ERα(%)	PR(%)	ERβ(%)	ERβ1(%)	ERβ_CX(%)
HER-2	例数	Ⅰ期	Ⅱ期	Ⅲ期	Ⅳ期	阳性数	阴性数	阳性率	ERα(%)	PR(%)	ERβ(%)	ERβ1(%)	ERβ_CX(%)
()	51	6	32	11	2	21	30	41.18%	0.00(40.00)	50.00(80.00)	15.00(70.00)	0.00(50.00)	35.00(35.00)
(-)	53	9	33	9	2	28	25	52.83%	80.00(84.98)	60.00(70.00)	50.00(67.50)	75.00(32.50)	75.00(47.50)
统计量		-0.806^a				1.417^b			-4.825^a	-2.171^a	-2.137^a	-5.509^a	-3.663^a
P值		0.420				0.234			0.000	0.030	0.033	0.000	0.000

Please choose a citation manager

Content to export